To address this issue, pharmacokinetic studies are necessary to compare blood drug concentration differences between liver cancer and liver failure patients, combined with CYP3A4 genetic polymorphism analysis, to optimize individualized dosing regimens. Here, CYP3A4 is linked to liver cancer.